Characterizing Magnitude and Selectivity of Attrition in a Study of Mild Cognitive Impairment

D Facal1, O Juncos-Rabadán, J Guardia-Olmos

  • 1D. Facal, University of Santiago de Compostela, Department of Developmental Psychology, Spain, david.facal@usc.es.

Abstract

Insights

Attrition in mild cognitive impairment (MCI) studies is a challenge. This study found that while 21.5% of participants dropped out, their cognitive performance did not differ, suggesting MCI attrition may not bias results.

Area of Science:

  • Neuroscience
  • Gerontology
  • Psychology

Background:

  • Longitudinal studies on cognitive aging face significant challenges with participant attrition.
  • Attrition risks underestimating cognitive decline in studies of mild cognitive impairment (MCI).

Purpose of the Study:

  • To characterize the magnitude and selectivity of attrition in a mild cognitive impairment (MCI) study.
  • To identify factors predicting participant dropout in MCI research.

Main Methods:

  • Recruited 42 multiple-domain amnestic MCI, 71 single-domain amnestic MCI, 35 non-amnestic MCI, and 318 healthy controls.
  • Conducted extensive baseline neuropsychological evaluations and a follow-up assessment.
  • Utilized data on comorbidity, social activities, and memory training for prediction.

Main Results:

  • 21.5% of participants did not complete the follow-up assessment.
  • No significant differences in cognitive performance were found between respondents and non-returners within the MCI group.
  • Baseline data on comorbidity, social activities, and memory training predicted follow-up status.

Conclusions:

  • Participant attrition in MCI studies may not necessarily lead to biased cognitive performance estimates.
  • Identifying potential non-returners is crucial for developing targeted retention strategies.
  • Minimizing attrition is essential for the validity and reliability of findings in MCI research.

Related Concept Videos

Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
804
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K